Surufatinib Plus Gemcitabine and Nab-paclitaxel vs. Gemcitabine Plus Nab-paclitaxel in Neoadjuvant Therapy for High - Risk Resectable or Borderline Resectable Pancreatic Cancer

NCT07436741 · clinicaltrials.gov ↗

PHASE3

Phase

NOT_YET_RECRUITING

Status

106

Enrollment

OTHER

Sponsor class

Conditions

Pancreatic Cancer, Adult

Interventions

DRUG: surufatinib + gemcitabine + nab-paclitaxel
DRUG: gemcitabine + nab-paclitaxel

Sponsor

Tianjin Medical University Cancer Institute and Hospital